An economic case for a vaccine to prevent group A streptococcus skin infections

Jeffrey W. Cannon, Susan Jack, Yue Wu, Jane Zhang, Michael G. Baker, Elizabeth Geelhoed, John Fraser, Jonathan R. Carapetis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Group A streptococcus (GAS) causes an exceptionally diverse range of diseases, raising questions about the optimal product characteristics of a commercially viable vaccine. The objectives of this study were to (1) estimate the current health and economic burdens caused by 24 diseases attributable to GAS each year in Australia and (2) use these estimates to explore the value of a GAS vaccine for different clinical indications, age schedules, and population groups. Methods: For objective 1, we estimated the population heath and economic burdens by synthesising data from administrative databases, nationally representative surveys, literature reviews, public reimbursement schedules, and expert opinion. For objective 2, we modelled the prospective lifetime burden of GAS for all infants from birth, for children from 5 years of age, and for adults from 65 years of age. A vaccine was assumed to reduce each GAS disease by 70% for a period of 10 years, and the difference in outcomes between vaccinated and non-vaccinated cohorts were used to calculate the cost-effective value of vaccination. Results: The annual health and economic burdens of GAS diseases totalled 23,528 disability-adjusted life years and AU$185.1 million in healthcare costs respectively; approximately half of each measure was due to cellulitis, followed by other skin infections and throat infections. Reducing the incidence of throat infections, skin infections, and cellulitis in non-Indigenous cohorts resulted in 30%, 33%, and 28% of the total vaccine value for an infant schedule (cost-effective vaccine price AU$260 per course); 47%, 26%, and 22% of the value for a child schedule (AU$289); and 2%, 15% and 74% for an adult schedule (AU$489). Conclusions: A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability, with a cost-effective price in line with other recently-licensed and funded vaccines in Australia.

Original languageEnglish
Pages (from-to)6968-6978
Number of pages11
JournalVaccine
Volume36
Issue number46
DOIs
Publication statusPublished - 12 Nov 2018

Fingerprint

Streptococcus
Vaccines
Economics
vaccines
economics
Skin
Appointments and Schedules
cellulitis
Cellulitis
Infection
throat
infection
Pharynx
Costs and Cost Analysis
disability-adjusted life year
health care costs
childbirth
Quality-Adjusted Life Years
expert opinion
Health

Cite this

Cannon, J. W., Jack, S., Wu, Y., Zhang, J., Baker, M. G., Geelhoed, E., ... Carapetis, J. R. (2018). An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine, 36(46), 6968-6978. https://doi.org/10.1016/j.vaccine.2018.10.001
Cannon, Jeffrey W. ; Jack, Susan ; Wu, Yue ; Zhang, Jane ; Baker, Michael G. ; Geelhoed, Elizabeth ; Fraser, John ; Carapetis, Jonathan R. / An economic case for a vaccine to prevent group A streptococcus skin infections. In: Vaccine. 2018 ; Vol. 36, No. 46. pp. 6968-6978.
@article{466c5781f1324142b5286a471122f516,
title = "An economic case for a vaccine to prevent group A streptococcus skin infections",
abstract = "Background: Group A streptococcus (GAS) causes an exceptionally diverse range of diseases, raising questions about the optimal product characteristics of a commercially viable vaccine. The objectives of this study were to (1) estimate the current health and economic burdens caused by 24 diseases attributable to GAS each year in Australia and (2) use these estimates to explore the value of a GAS vaccine for different clinical indications, age schedules, and population groups. Methods: For objective 1, we estimated the population heath and economic burdens by synthesising data from administrative databases, nationally representative surveys, literature reviews, public reimbursement schedules, and expert opinion. For objective 2, we modelled the prospective lifetime burden of GAS for all infants from birth, for children from 5 years of age, and for adults from 65 years of age. A vaccine was assumed to reduce each GAS disease by 70{\%} for a period of 10 years, and the difference in outcomes between vaccinated and non-vaccinated cohorts were used to calculate the cost-effective value of vaccination. Results: The annual health and economic burdens of GAS diseases totalled 23,528 disability-adjusted life years and AU$185.1 million in healthcare costs respectively; approximately half of each measure was due to cellulitis, followed by other skin infections and throat infections. Reducing the incidence of throat infections, skin infections, and cellulitis in non-Indigenous cohorts resulted in 30{\%}, 33{\%}, and 28{\%} of the total vaccine value for an infant schedule (cost-effective vaccine price AU$260 per course); 47{\%}, 26{\%}, and 22{\%} of the value for a child schedule (AU$289); and 2{\%}, 15{\%} and 74{\%} for an adult schedule (AU$489). Conclusions: A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability, with a cost-effective price in line with other recently-licensed and funded vaccines in Australia.",
keywords = "Burden, Cost-effective, Economic, Group A streptococcus, Streptococcus pyogenes, Vaccine",
author = "Cannon, {Jeffrey W.} and Susan Jack and Yue Wu and Jane Zhang and Baker, {Michael G.} and Elizabeth Geelhoed and John Fraser and Carapetis, {Jonathan R.}",
year = "2018",
month = "11",
day = "12",
doi = "10.1016/j.vaccine.2018.10.001",
language = "English",
volume = "36",
pages = "6968--6978",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "46",

}

Cannon, JW, Jack, S, Wu, Y, Zhang, J, Baker, MG, Geelhoed, E, Fraser, J & Carapetis, JR 2018, 'An economic case for a vaccine to prevent group A streptococcus skin infections' Vaccine, vol. 36, no. 46, pp. 6968-6978. https://doi.org/10.1016/j.vaccine.2018.10.001

An economic case for a vaccine to prevent group A streptococcus skin infections. / Cannon, Jeffrey W.; Jack, Susan; Wu, Yue; Zhang, Jane; Baker, Michael G.; Geelhoed, Elizabeth; Fraser, John; Carapetis, Jonathan R.

In: Vaccine, Vol. 36, No. 46, 12.11.2018, p. 6968-6978.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An economic case for a vaccine to prevent group A streptococcus skin infections

AU - Cannon, Jeffrey W.

AU - Jack, Susan

AU - Wu, Yue

AU - Zhang, Jane

AU - Baker, Michael G.

AU - Geelhoed, Elizabeth

AU - Fraser, John

AU - Carapetis, Jonathan R.

PY - 2018/11/12

Y1 - 2018/11/12

N2 - Background: Group A streptococcus (GAS) causes an exceptionally diverse range of diseases, raising questions about the optimal product characteristics of a commercially viable vaccine. The objectives of this study were to (1) estimate the current health and economic burdens caused by 24 diseases attributable to GAS each year in Australia and (2) use these estimates to explore the value of a GAS vaccine for different clinical indications, age schedules, and population groups. Methods: For objective 1, we estimated the population heath and economic burdens by synthesising data from administrative databases, nationally representative surveys, literature reviews, public reimbursement schedules, and expert opinion. For objective 2, we modelled the prospective lifetime burden of GAS for all infants from birth, for children from 5 years of age, and for adults from 65 years of age. A vaccine was assumed to reduce each GAS disease by 70% for a period of 10 years, and the difference in outcomes between vaccinated and non-vaccinated cohorts were used to calculate the cost-effective value of vaccination. Results: The annual health and economic burdens of GAS diseases totalled 23,528 disability-adjusted life years and AU$185.1 million in healthcare costs respectively; approximately half of each measure was due to cellulitis, followed by other skin infections and throat infections. Reducing the incidence of throat infections, skin infections, and cellulitis in non-Indigenous cohorts resulted in 30%, 33%, and 28% of the total vaccine value for an infant schedule (cost-effective vaccine price AU$260 per course); 47%, 26%, and 22% of the value for a child schedule (AU$289); and 2%, 15% and 74% for an adult schedule (AU$489). Conclusions: A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability, with a cost-effective price in line with other recently-licensed and funded vaccines in Australia.

AB - Background: Group A streptococcus (GAS) causes an exceptionally diverse range of diseases, raising questions about the optimal product characteristics of a commercially viable vaccine. The objectives of this study were to (1) estimate the current health and economic burdens caused by 24 diseases attributable to GAS each year in Australia and (2) use these estimates to explore the value of a GAS vaccine for different clinical indications, age schedules, and population groups. Methods: For objective 1, we estimated the population heath and economic burdens by synthesising data from administrative databases, nationally representative surveys, literature reviews, public reimbursement schedules, and expert opinion. For objective 2, we modelled the prospective lifetime burden of GAS for all infants from birth, for children from 5 years of age, and for adults from 65 years of age. A vaccine was assumed to reduce each GAS disease by 70% for a period of 10 years, and the difference in outcomes between vaccinated and non-vaccinated cohorts were used to calculate the cost-effective value of vaccination. Results: The annual health and economic burdens of GAS diseases totalled 23,528 disability-adjusted life years and AU$185.1 million in healthcare costs respectively; approximately half of each measure was due to cellulitis, followed by other skin infections and throat infections. Reducing the incidence of throat infections, skin infections, and cellulitis in non-Indigenous cohorts resulted in 30%, 33%, and 28% of the total vaccine value for an infant schedule (cost-effective vaccine price AU$260 per course); 47%, 26%, and 22% of the value for a child schedule (AU$289); and 2%, 15% and 74% for an adult schedule (AU$489). Conclusions: A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability, with a cost-effective price in line with other recently-licensed and funded vaccines in Australia.

KW - Burden

KW - Cost-effective

KW - Economic

KW - Group A streptococcus

KW - Streptococcus pyogenes

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85054846229&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.10.001

DO - 10.1016/j.vaccine.2018.10.001

M3 - Article

VL - 36

SP - 6968

EP - 6978

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 46

ER -